What is Genetika?
Genetika is an Israeli-based company founded by a team of scientists dedicated to revolutionizing mental health treatment. Their core technology enables an in-vitro screening process using a blood sample to predict the most effective antidepressant for an individual patient. This precision medicine approach aims to move beyond trial-and-error, offering a more targeted and efficient path to recovery for those suffering from mental health conditions. The company's platform represents a significant advancement in pharmacogenomics for psychiatric care.
How much funding has Genetika raised?
Genetika has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2021): $10M with participation from GreyBird Ventures, Meron Capital, Jumpspeed Ventures, and Sapir Venture Partners
Key Investors in Genetika
GreyBird Ventures
GreyBird Ventures is an investment firm specializing in unique diagnostic technologies within the precision medicine sector. They support companies aiming to advance healthcare through innovative diagnostic solutions.
Meron Capital
Meron Capital focuses on providing capital, strategic expertise, and network access to early-stage technology startups, particularly those with high growth potential.
Jumpspeed Ventures
Jumpspeed Ventures is a micro-fund based in Jerusalem that invests in early-stage software startups originating from the local ecosystem, offering seed and pre-seed financing.
What's next for Genetika?
With its recent major strategic investment, Genetika is poised for significant expansion and further development of its groundbreaking medicine platform. This enterprise-level backing suggests a strong market validation and confidence in the company's scientific approach. The capital will likely be directed towards scaling operations, advancing clinical validation, and potentially broadening the application of their predictive technology to other areas of mental health treatment. Genetika's trajectory indicates a move towards broader market penetration and establishing itself as a leader in personalized psychiatric care.
See full Genetika company page
